Immunogenicity and safety of pandemic H1N1 2009 influenza vaccine for HIV-1 patients

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F12%3A43907065" target="_blank" >RIV/00216208:11120/12:43907065 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.4149/av_2012_04_349" target="_blank" >http://dx.doi.org/10.4149/av_2012_04_349</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.4149/av_2012_04_349" target="_blank" >10.4149/av_2012_04_349</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Immunogenicity and safety of pandemic H1N1 2009 influenza vaccine for HIV-1 patients

Popis výsledku v původním jazyce

The advent of the 2009 H1N1 pandemic influenza has raised concerns about the immunogenicity and safety of vaccines against the new virus, especially in immunocompromised individuals. In our study we evaluated the immunogenicity and safety of pandemic influenza vaccine in 34 HIV-1 infected patients. For immunization was we used a single dose of adjuvanted inactivated split-virion pandemic H1N1 influenza vaccine containing 3.75 ug of hemagglutinin (A/California/7/2009) and adjuvant AS03. Two serum sampleswere collected from each patient - first on day 0, just before vaccination and the other on day 28, after vaccination. Antibody production was tested by hemagglutinin inhibition assay according to the World Health Organization methodology. The mean baseline CD4+ T lymphocyte count was 511/ul (range 90-1151). After vaccination, protective titers >1:40 were found in 24 (70.5%) vaccines, and at least a fourfold increase in antibody titers was detected in 27 vaccines (79.4%). Seroconversion

Název v anglickém jazyce

Immunogenicity and safety of pandemic H1N1 2009 influenza vaccine for HIV-1 patients

Popis výsledku anglicky

The advent of the 2009 H1N1 pandemic influenza has raised concerns about the immunogenicity and safety of vaccines against the new virus, especially in immunocompromised individuals. In our study we evaluated the immunogenicity and safety of pandemic influenza vaccine in 34 HIV-1 infected patients. For immunization was we used a single dose of adjuvanted inactivated split-virion pandemic H1N1 influenza vaccine containing 3.75 ug of hemagglutinin (A/California/7/2009) and adjuvant AS03. Two serum sampleswere collected from each patient - first on day 0, just before vaccination and the other on day 28, after vaccination. Antibody production was tested by hemagglutinin inhibition assay according to the World Health Organization methodology. The mean baseline CD4+ T lymphocyte count was 511/ul (range 90-1151). After vaccination, protective titers >1:40 were found in 24 (70.5%) vaccines, and at least a fourfold increase in antibody titers was detected in 27 vaccines (79.4%). Seroconversion

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FN - Epidemiologie, infekční nemoci a klinická imunologie

OECD FORD obor

—

Projekt

—

Návaznosti

S - Specificky vyzkum na vysokych skolach

Rok uplatnění

2012

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Acta Virologica

ISSN

0001-723X

e-ISSN

—

Svazek periodika

56

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

SK - Slovenská republika

Počet stran výsledku

3

Strana od-do

349-351

Kód UT WoS článku

000313403400011

EID výsledku v databázi Scopus

—